Skip to main content
Lifecare ASA logo

Lifecare ASA — Investor Relations & Filings

Ticker · LIFE ISIN · NO0013355859 LEI · 254900D88MYGZ7JD5P39 OL Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2023-10-17 Regulatory Filings
Country NO Norway
Listing OL LIFE

About Lifecare ASA

https://lifecare.no/

Lifecare ASA is a clinical-stage medical sensor company specializing in the development of nanotechnology for medical applications. Its core activity involves creating miniaturized, implantable, and long-term nanobiosensors for the continuous monitoring of various body analytes. The company's primary focus is on developing a sensor for correct and continuous glucose monitoring to improve diabetes management. The business model is based on developing and licensing its proprietary sensor technology to facilitate the production and sale of advanced medical devices.

Recent filings

Filing Released Lang Actions
Confirmation from Norwegian Medicines Agency
Regulatory Filings Classification · 1% confidence The document is a press release from Lifecare AS announcing a regulatory confirmation from the Norwegian Medicines Agency regarding their Sencell CGM product being classified as a medical device for veterinary use, not a medicinal product, and noting the lack of specific regulations for animal medical devices in Norway. This announcement pertains to regulatory status and market entry strategy, but it is not a formal regulatory filing (like a 10-K or AR), nor is it a transcript, earnings release, or dividend notice. It is a specific update concerning legal/regulatory matters impacting the business. Given the options, 'Legal Proceedings Report (LTR)' is the closest fit as it deals with official governmental/regulatory findings that impact the product's legal standing and market path, although 'Regulatory Filings (RNS)' could also be considered as a general announcement. However, since it details a specific governmental assessment on product classification and market requirements, LTR is more precise than the general RNS fallback, as it directly addresses a regulatory finding/ruling that affects the company's legal compliance path. Given the nature of the content (confirmation/ruling on product status), LTR is the most appropriate specific category.
2023-10-17 English
Lifecare – Progress as planned towards ISO 13485 compliance
Regulatory Filings Classification · 1% confidence The document is a short press release dated October 12th, 2023, announcing progress towards ISO 13485 compliance, which is a quality management system standard for medical devices. It mentions future events (audit in November 2023, certificate expected early 2024) and references previous communications like the semi-annual report. Since this is a specific operational update that doesn't fit the definitions for Earnings Release (ER), Interim Report (IR), or a formal regulatory filing like 10-K, and it is not a management change (MANG) or director dealing (DIRS), it falls best under the general category for regulatory or significant operational announcements that aren't explicitly covered elsewhere. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-financial, non-meeting related corporate news releases that are mandatory disclosures.
2023-10-12 English
Lifecare- Purchase software for automated production
Regulatory Filings Classification · 1% confidence The document is a short press release dated October 2nd, 2023, announcing a specific operational update: Lifecare AS placing a purchase order for automated production software related to their Continuous Glucose Monitor (CGM) development. It references previous communications (semi-annual report) and sets future milestones (automated production line by Q2 2024). This type of announcement, detailing operational progress, equipment procurement, and strategic steps that are not standard financial reports (10-K, IR, ER) or mandatory regulatory filings like insider trading (DIRS) or major shareholding changes (MRQ), fits best under a general regulatory announcement or news release category. Since it is not a formal financial report, a dividend notice, or a management change, and it is a specific, material update, it is classified as a Regulatory Filing (RNS) as a general disclosure mechanism, although it could also be considered a Capital/Financing Update (CAP) if the purchase order implied a significant financial commitment, but the focus here is on operational progress. Given the context of providing material, non-financial operational news, RNS is the most appropriate general disclosure category.
2023-10-02 English
Lifecare to present company update at Redeye Medtech & Diagnostics Seminar today
Investor Presentation Classification · 1% confidence The document is titled "Company presentation September 2023" and contains numerous slides detailing product development (Sencell Glucose sensor), partnership information (Sanofi agreement), market analysis (Diabetes prevalence, CGM market size), clinical accuracy data, revenue projections, and lists of the Board of Directors, Officers, and Scientific Advisors. This structure is characteristic of an Investor Presentation (IP) designed to communicate strategy, technology, and financial outlook to potential and current investors. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a short announcement (RPA/RNS).
2023-09-26 English
Lifecare to present company update at Redeye Medtech & Diagnostics Seminar today
Report Publication Announcement Classification · 1% confidence The document is a short announcement stating that Lifecare AS will present a company update at the Redeye Medtech & Diagnostics Seminar on September 26, 2023. It explicitly mentions that the 'presentation deck is enclosed' and provides a link to follow the broadcast. Because the document is very short (1750 chars) and its primary function is to announce the availability of presentation materials for an event, it fits the definition of a Report Publication Announcement (RPA) or potentially a general Regulatory Filing (RNS). Given the context of presenting company updates and enclosing the deck, RPA is the most specific fit, as it announces the publication/availability of presentation materials for an event, rather than being the presentation itself (IP) or a transcript (CT).
2023-09-26 English
Lifecare announces presentation of additional clinical data from study LFS-SEN-001
Regulatory Filings Classification · 1% confidence The document is a press release from Lifecare AS announcing that additional clinical data from study LFS-SEN-001 will be presented at an upcoming international diabetes conference (DTM). It details the content of the presentation (poster) and references previous data presented at the ADA. This is a general corporate announcement regarding scientific/clinical updates and presentation schedules, not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is an announcement about scientific/clinical progress and presentation, it does not fit neatly into the defined categories like M&A (TAR), Capital (CAP), or Director's Dealing (DIRS). The most appropriate fallback category for a general corporate update that doesn't fit elsewhere, especially one related to ongoing development and external presentations, is Regulatory Filings (RNS), as it serves as a general disclosure mechanism.
2023-09-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.